Genome Research Technology Offers

Jordi Reverter posted this:
Licensing Manager at Institut Català de Nanociència i Nanotecnologia

New Nanoporous Graphene material A bottom up unique method build the holy graphene from molecular blocks. The molecular blocks used define the size and shape of the pores, which are identical with atomic precision. We can also control the chemical functionalization of the material. This material has semiconducting properties with a bandgap similar to Si, opening new applications for graphene-based materials. This new material can be used for sieving, sensing, (opto)electronics or its combinations.

New Nanoporous Graphene material

Lidia Aguilera posted this:
Technology Transfer Officer at University of Luxembourg

Metabolomics Platform - Luxembourg Centre for Systems Biomedicine The LCSB Metabolomics Platform is specialized in developing and applying mass spectrometry-based comprehensive analysis methods of small molecules in complex biological matrices. Our Platform works with national and international partners from academia and industry to help them reach their research goals. To address the needs in this fast-changing field, our Platform continuously develops new analytical and tailor-made methods in response to upcoming biological and biomedical questions.

Metabolomics Platform - Luxembourg Centre for Systems Biomedicine

Lidia Aguilera posted this:
Technology Transfer Officer at University of Luxembourg

AQUATIC PLATFORM - Luxembourg Centre for Systems Biomedicine The LCSB Aquatic Platform is centred around the use of zebrafish (Danio rerio), a vertebrate model with high genetic and physiologic similarity to humans. This versatile, reliable model organism is widely used for the in vivo study of developmental biology, gene function, drug discovery and pathophysiological aspects of various human diseases such as epilepsy, rare diseases, neurodegenerative disorders, among others.

AQUATIC PLATFORM - Luxembourg Centre for Systems Biomedicine

Yissum - Research Development Company of the Hebrew University posted this:

A novel target for the treatment of genetic diseases caused by nonsense mutations A novel target for the treatment of genetic diseases caused by nonsense mutations Project ID : 6-2018-4579

Yissum - Research Development Company of the Hebrew University posted this:

Novel Indoline Derivatives as Anti-Inflammatory Agents for the Treatment of Diabetes Novel Indoline Derivatives as Anti-Inflammatory Agents for the Treatment of Diabetes Project ID : 7-2015-3171

Yissum - Research Development Company of the Hebrew University posted this:

Novel Transdermal Delivery System of Cannabinoids Cluster9 Cannabinoids Transdermal, enhanced and modulated administration due to an innovative biphasic composition Project ID : 6-2016-4334

NDI Foundation posted this:

Strain of bacteriorhodopsin-BR Bacteriorhodopsin (BR) is the newest biotechnological product that will make a revolution in many spheres of life: from medicine to defense. Data on the production of the BR in the world is hidden. From open sources - the only seller (and, possibly, producer) is an American company SIGMA, selling BR for research. We offer developed strain of BR. A method of producing allows to get BR in large quantities to several kg. The strain is certified and stored in special depositories. BR has unique qualities - the main one is - memory. For BR, it was necessary to find a special strain - producer of BR. Just several countries has the strain (USA, Russia, ..), other data hidden. We also developed such an unique strain.

Yissum - Research Development Company of the Hebrew University posted this:

Diagnostic test for epilepsy in Arabian horses Cluster11 Project ID : 24-2017-4415

Diagnostic test for epilepsy in Arabian horses

Yissum - Research Development Company of the Hebrew University posted this:

Innovative Skin Non-penetrating Products Containing Sunscreen Molecules Keywords: cosmetics, sunscreens Project ID : 6-2006-191

Yissum - Research Development Company of the Hebrew University posted this:

CBD treatment for Hepatic Encephalopathy, Liver Cirrhosis and NASH A method for the treatment of hepatic encephalopathy comprising administering to a subject in need of such treatment an effective amount of D9-tetrahydrocannabinol (THC) or Cannabidiol. keywords: hepatic, encephalopathy Originally: 12-2007-1885, 12-2007-1878 12-2006-577- 3 projects combined into one Project ID : 12-2006-577

Yissum - Research Development Company of the Hebrew University posted this:

Novel Compounds for the treatment of obesity Novel Compounds for the treatment of obesity Project ID : 6-2008-1996

Yissum - Research Development Company of the Hebrew University posted this:

Floating sustained release of antioxidants Floating Sustained Release Delivery systems of Polyphenols Project ID : 6-2009-2215

Yissum - Research Development Company of the Hebrew University posted this:

Novel Compounds for the Treatment and Prevention of Autism beta- carotene as treatment for autism Project ID : 6-2014-3058

Yissum - Research Development Company of the Hebrew University posted this:

New Formulations for Oral, Nasal, Transdermal and Rectal Cannabinoids Cluster9 CBD Project ID : 6-2017-4448

Yissum - Research Development Company of the Hebrew University posted this:

Treating Skin Toxicities Caused by Biological Cancer Drugs Applying Topical Specific Inhibitors to the Anti-Cancer Drugs Cluster8 Many of the antineoplastic tyrosine kinase inhibitors are associated with prominent and sometimes dose-limiting dermatologic complications. Of severe clinical implication are the specific EGFR inhibitors. Most patients treated with these drugs suffer from severe impairment to their quality of life and require reduction or interruption in the anti-cancer drug protocols. Treatment strategies today for treating skin toxicities from EGFR inhibitors show limited benefit and most patients require dose reductions or interruptions to the anti-cancer treatment protocols. Our proposal focuses on the development of a novel approach using formulation for treating skin toxicities caused by anti-neoplastic EGFR inhibitors by applying topical compounds that specifically and locally block the anti-cancer drugs. Our preliminary results have shown that blocking EGFR inhibitors binding to EGFR prevents keratinocyte death. We have identified small compounds that block EGFR inhibitors binding to its receptor and have developed topical slow release system that can deliver the target compounds to the hair follicle which is a major target for skin rash caused by EGFR inhibitors. Our novel approach will improve the quality of life of patients suffering from skin toxicity and help maintain an optimal anti-neoplastic dose thereby allowing more patients to receive full dose anti-cancer therapy and improve response to therapy Project ID : 6-2017-4450

1
2
3
4
5